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The processes leading to anticancer drug resistance are not completely unraveled. To get insights 
into the underlying mechanisms, we compared colon carcinoma cells sensitive to doxorubicin with 
their resistant counterpart. We found that resistant cells are growth retarded, and show staminal 
and ultrastructural features profoundly different from sensitive cells. The resistant phenotype is 
accompanied by the upregulation of the magnesium transporter MagT1 and the downregulation of the 
ion channel kinase TRPM7. We demonstrate that the different amounts of TRPM7 and MagT1 account 
for the different proliferation rate of sensitive and resistant colon carcinoma cells. It remains to be 
verified whether they are also involved in the control of other “staminal” traits.
TRPM7, which belongs to the transient receptor potential melastatin subfamily, is a bifunctional protein com-
prising an ion channel region covalently linked to a serine/threonine α -kinase domain1,2. TRPM7, which is 
ubiquitously expressed, conducts several divalent cations3 and contributes to intracellular magnesium (Mg) 
homeostasis4, while the α -kinase phosphorylates annexin A1, myosin II, eEF2 and PLCγ 25–8. It was shown that 
the TRPM7 kinase domain can be proteolytically cleaved and then transported to the nucleus where it phos-
phorylates histones thus contributing to remodeling chromatin9. Knock-out studies in mice and zebrafish 
demonstrated that TRPM7 is necessary for early embryonic development4,10–12. Silencing TRPM7 in cultured 
cells disclosed its implication in the regulation of crucial cellular processes, among which cell adhesion, sur-
vival, migration, differentiation and proliferation1. In vitro, silencing TRPM7 inhibits cell growth and impairs 
cell viability of all cell types tested1, apart from human macrovascular endothelial cells13,14. Recently, TRPM7 
has emerged as a potential player in cancer15. TRPM7 over-expression has been reported in human breast and 
pancreatic cancer and correlates with clinico-pathologic parameters15. Moreover, TRPM7 is required for prolif-
eration and migration of several types of tumor cells15. It is noteworthy that the growth of TRPM7 deficient cells 
can be in part rescued by the overexpression of another ubiquitously expressed transporter, i.e. Mg transporter 
1 (MagT1)16. MagT1 is a plasma membrane transporter highly selective for Mg17. Its upregulation is described 
in hepatomas18 while its low expression correlates with a poor outcome in patients with ovarian carcinoma19. 
In T-lymphocytes MagT1 mediates a rapid Mg influx after receptor stimulation, thus indicating that MagT1 is 
implicated in immune response16,20,21.
Since very little is known about these transporters in drug resistance, we focused on TRPM7 and MagT1 
expression in LoVo cells sensitive (LoVo-S) or resistant (LoVo-R) to doxorubicin (DXR). In a recent study, we 
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have demonstrated lower amounts of TRPM7 in LoVo-R than in LoVo-S22. Interestingly, silencing TRPM7 pro-
tects LoVo-S from the toxic effects of DXR, while calpeptin-induced upregulation of TRPM7 impairs the resist-
ance of LoVo-R to the drug, thus indicating that TRPM7 might play a role in chemoresistance22. Here we broaden 
our previous studies by comparing the morphology, proliferation, expression and role of TRPM7 and MagT1 in 
LoVo-R and LoVo-S.
Results
LoVo-R vs LoVo-S: morphology and growth rate. Because cell shape is related to cellular function23, 
initially we studied the morphology of LoVo-S and LoVo-R. Supplementary Figure S1A shows the morphology of 
LoVo-S and -R by optical microscopy. By electron microscopy (Fig. 1), both LoVo-S and LoVo-R exhibited a high 
nucleocytoplasmic ratio, a well-preserved ultrastructure and a nucleus with dispersed chromatin.
LoVo-S showed an elongated flattened morphology, appeared partially overlapped, connected by junctions in 
some cases, and arranged with the basolateral membrane adhering to the plastic dish. The cells seem to be polar-
ized and some microvilli can be observed on the luminal surface of the cells (Fig. 1a). On the contrary, LoVo-R 
exhibited a round shape, were loosely tethered to the substrate, presented surface plasma membrane protrusions 
distributed over the entire surface, and released many extracellular vesicles (Fig. 1b). Ultrastructural analysis also 
highlighted differences in the mitochondria, which were more condensed and sometimes with dilated cristae in 
LoVo-R (Fig. 1d) vs LoVo-S (Fig. 1c).
We also evaluated the levels of CD133, a colon cancer stem cell marker that tends to accumulate in cell protru-
sions, and ABCB1/P-glycoprotein (PgP), which pumps out various anticancer drugs including DXR. Figure 1e 
shows that CD133 and PgP were overexpressed in LoVo-R, as detected by cytofluorimetry and western blot, 
respectively (Supplementary S1E).
When we compared LoVo-R and -S for their proliferative behaviour, LoVo-R resulted growth retarded 
(Fig. 2a). In particular, we noticed a long lag phase in LoVo-R, which entered in the exponential phase after 48 h, 
while LoVo-S started to double after 24 h from seeding. LoVo-S reached the plateau phase between 72 and 96 h, 
when LoVo-R were still in the exponential phase. These results were confirmed when we evaluated cell cycle dis-
tribution by fluorescence-activated cell sorting (FACS) (Fig. 2b). Exponential growth occurred between 24 and 
72 h in LoVo-S, and between 72 and 144 h in LoVo-R. The percentage of LoVo-S in the S phase started to decrease 
at 96 h, while the S phase of LoVo-R remained constant being still maximal after 96 h and tended to decrease only 
at 144 h (Fig. 2b).
LoVo-R vs LoVo-S: expression and role of TRPM7 and MagT1. At different time points during the 
experiment in Fig. 2, we evaluated the levels of TRPM7 and MagT1 by western blot. We found that TRPM7 is 
lower while MagT1 is higher in LoVo-R than in LoVo-S at all the time points tested (Figs 3 and Supplementary S3). 
Moreover, by immunofluorescence, TRPM7 has a similar localization in LoVo-R and -S with a clear nuclear 
exclusion (Supplementary S3).
Because TRPM7 has been linked to the control of cell proliferation1, we determined whether TRPM7 might 
participate to the regulation of LoVo cell growth. Initially, we treated LoVo-S and -R with 2-aminoethoxydiphenyl 
Figure 1. Ultrastructural features and biochemical markers of LoVo-S and LoVo-R cells. LoVo-S (a) 
and -R (b) cultured in a 2D-monolayer were analyzed by TEM. LoVo-S (c) and -R (d) were analyzed at a 
higher magnification. Scale bar = 1 μ m. (e) The levels of CD133 and ABCB1/P-glycoprotein were analysed by 
cytofluorimetry and western blot, respectively. For full-length blot and FACS profile, see Supplementary 1E.
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borate (2-APB, 50 μ M), a commonly used non-specific blocker of TRPM7 activity22. While no effect was observed 
in LoVo-R upon exposure to the compound, we found that 2-APB hindered LoVo-S cell growth (Fig. 4a). Then 
we transiently transfected LoVo-S with a specific siRNA for TRPM7 or with a non-silencing, scrambled siRNA 
as a control. After 24 h, Real-Time PCR showed a marked reduction of TRPM7 transcript (Fig. 4b). By western 
blot we detected dramatically reduced amounts of TRPM7 up to 72 h after silencing and no modulation of MagT1 
(Figs 4c and Supplementary S4C). TRPM7 downregulation correlated with the reduction of LoVo-S cell growth 
(Fig. 4d). The same siRNA exerted no significant effects on the growth of LoVo-R (Supplementary S4D). The role 
of TRPM7 in modulating LoVo cell proliferation is supported also by experiments on LoVo-R cultured in the 
presence of the calpain inhibitor calpeptin. The concentration of calpeptin (5 μ g/ml) used in this study exerts no 
cytotoxic effect22. Figure 5a and b show that calpeptin upregulated TRPM7, but not MagT1 (Supplementary S5A), 
and induced cell proliferation.
Then, we transiently silenced MagT1 in LoVo-R. After 24 h Real-Time PCR demonstrated the downregulation 
of MagT1 transcript (Fig. 6a). At various time points after silencing, western blot showed the reduction of the 
total amounts of MagT1 (Figs 6b and Supplementary S6B). It is noteworthy that TRPM7 is upregulated early and 
transiently during MagT1 silencing. However, cell proliferation was severely impaired in MagT1-deficient LoVo-R 
(Fig. 6c).
Discussion
We have previously demonstrated that TRPM7 expression is lower in confluent LoVo-R than in confluent LoVo-S, 
and contributes to render the cells resistant to DXR22. Here we show that the resistant phenotype is characterized 
not only by low amounts of TRPM7 but also by high levels of MagT1. These differences are maintained in sparse 
and in exponentially growing LoVo cells and are independent from their cell cycle position. It is interesting to 
recall that similar results were obtained in human endothelial cells from the umbilical vein for TRPM713 and 
MagT1 (unpublished results).
Several studies have shown that TRPM7 is required for the proliferation of normal and tumor cells1,15. Our 
results are in accordance with these findings since we show that (i) LoVo-R, which express low amounts of 
TRPM7, grow slower than LoVo-S; (ii) calpeptin-induced TRMP7 accelerates LoVo-R proliferation; and (iii) 
silencing TRPM7 hinders LoVo-S cell proliferation. We rule out that TRPM7 contributes to the regulation of 
Figure 2. Proliferative behaviour of LoVo-S and LoVo-R cells. LoVo-S and LoVo-R cells were counted every 
24 h for 6 days. Data refer to three separate experiments in triplicate ± standard deviation. (a) LoVo-S and 
LoVo-R cells were harvested at different times after seeding and cell cycle distribution was analyzed by FACS.
Figure 3. TRPM7 and MagT1 in LoVo-S and LoVo-R. LoVo cells were harvested every 48 h for 6 days and 
lysed. Part of the sample (100 μ g) was run on a 10% SDS-PAGE and probed with anti-MagT1 antibodies. The 
same amounts of cell lysates were separated on a 8% SDS-PAGE and utilized for Western blot using anti-TRPM7 
antibodies. Blots were processed in parallel. Actin was used as a control of loading. Full-length blots and 
quantification are presented in Supplementary Figure S3.
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cell growth by impacting on intracellular Mg since we have shown an inverse correlation between total intracel-
lular magnesium and the levels of TRPM722. Since TRPM7 phosphorylates some proteins, we argue that silenc-
ing TRPM7 might impair the phosphorylation of its substrates. Among the phosphorylation targets of TRPM7, 
annexin 1 and phospholipase Cγ 5,8 are particularly challenging, because they are involved in the regulation of cell 
growth.
Far less is known about the involvement of MagT1 in cell proliferation. It is reported that the overexpression of 
MagT1 in TRPM7-deficient DT40 cells restores cell growth16. We found a marked inhibition of the proliferation 
of LoVo-R silencing MagT1 in spite of a transient induction of the levels of TRPM7. We hypothesize that such an 
upregulation does not reach the threshold necessary to sustain cell growth. It is noteworthy that silencing MagT1 
did not alter total intracellular Mg (Supplementary S6D). Moreover, since MagT1 is a subunit of the oligosac-
charyltransferase complex and, therefore, is implicated in protein glycosylation24, it is possible that its silencing 
impacts on post-translational modification of proteins involved in controlling cell proliferation.
It is also interesting to point that LoVo-R and not LoVo-S express the stem cell biomarker CD133, which 
is considered a putative marker for colorectal cancer stem cells25. This indicates that LoVo-R display a higher 
Figure 4. Effect of TRPM7 silencing on LoVo-S proliferation. (a) Cells were treated with the TRPM7 channel 
blocker 2-APB (50 μ M) and counted every 24 h for 3 days. Data are express as % of the control and refer to 
three separate experiments in triplicate ± standard deviation. (b) LoVo-S were transfected with a siRNA against 
TRPM7 or with a non-silencing siRNA. After 24 h RNA was extracted and Real-Time PCR performed using 
primers designed on TRPM7 sequence. (c) Western blot was performed on cell extracts of LoVo-S 24, 48 and 
72 h after exposure to siRNA. Actin was used as a control of loading. Full-length blots and quantification are 
presented in Supplementary Figure S4C. (d) LoVo-S treated as described above were counted every 24 h. Data 
are expressed as total cell number and refer to three separate experiments in triplicate ± standard deviation.
Figure 5. Effects of calpeptin on LoVo-R proliferation. LoVo-R cells were treated with calpeptin (5.0 μ g/ml)  
for 24, 48 and 72 h. (a) Western blot was performed on cell lysates with anti-TRPM7 and anti-MagT1 
antibodies. Actin was used to show that equal amounts of proteins were loaded per lane. Full-length blots 
and quantification are presented in Supplementary Figure S5A. (b) LoVo-R were counted every 24 h. Data are 
expressed as total cell number and refer to three separate experiments in triplicate ± standard deviation.
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stemness potential than LoVo-S, as suggested also by the marked differences of cell shape and by our previous 
results22. To this purpose, it should be highlighted that i) most primitive stem cells seem to grow slowly, and ii) 
they express detoxification molecules, i.e ABC transporters26. Indeed, LoVo-R grow slower and express higher 
amounts of PgP, which mediates DXR efflux26, than LoVo-S. Another issue to consider is that CD133 is selectively 
localized in microvilli and other plasma membrane protrusions27 and electron microscopy clearly shows that 
LoVo-R are richer in plasma membrane protrusions than LoVo-S. Electron microscopy also shows that the mito-
chondria in LoVo-R, while retaining a normal ultrastructure, have a dense matrix. It has been reported that cells 
with dense mitochondria are hypoxia-tolerant, and, consequently, generate adequate amounts of ATP by oxida-
tive phosphorylation28, a feature which is fundamental to boost the production of ATP necessary to extrude DXR 
via PgP and to cope with constant chemotherapeutic stress29. Moreover, an enhanced oxidative metabolism in 
drug-resistant vs drug-sensitive cells was demonstrated in glioma30. Accordingly, the metabolism of colon cancer 
cells shifts from glycolysis towards oxidative phosphorylation upon exposure to anticancer drugs31.
In conclusion, we demonstrate that resistant cells are more staminal than sensitive cells and this phenotype 
associates with different amounts of MagT1 and TRPM7, which are, in part, responsible for the different prolif-
eration of LoVo-R and LoVo-S.
Methods
Cell Culture. LoVo-S and LoVo-R (donated by Dr. P. Perego, Istituto Nazionale Tumori, Milano) were cultured 
in DMEM containing 10% fetal bovine serum and 2 mM glutamine, at 37 °C and 5% CO222.
To obtain a transient downregulation of MagT1 and TRPM7, we utilized the stealth siRNAs developed by 
Qiagen for TRPM722 and Invitrogen for MagT1. siRNAs targeting TRPM7 were transfected using HiPerFect 
Transfection Reagent (Qiagen) while for siRNAs targeting MagT1 we used Lipofectamine RNAiMAX 
(Invitrogen). Non-silencing, scrambled sequences were used as controls (CTR).
For proliferation assays, the cells were seeded at low density (10000 cells/cm2), trypsinized, stained with a 
trypan blue solution (0.4%) and counted using a cell counter (Logos Biosystems).
Cell cycle was analyzed by FACS. Briefly, 1 × 106 cells were centrifuged and resuspended in a hypotonic stain-
ing solution (Na3citrate 1 mg/mL, Nonidet 0.1%, Rnase 1 μ g/mL, Propidium Iodide 50 μ g/mL) and left overnight 
at 4 °C. Cells were analyzed on a Brite HS BioRad flow cytometer, and the PI fluorescence was excited at 360 nm 
and collected at 600 nM on a linear scale. The percentages of the cells in the different phases of the cycle were 
evaluated by using the Modifit software (Verity).
CD133 expression was evaluated by flow cytometry, using the AC133 mouse monoclonal antibody directly 
conjugated with phycoerythrin (Miltenyi Biotech).
Figure 6. MagT1 silencing and LoVo-R proliferation. LoVo-R were transfected with a siRNA against MagT1 
or with a non-silencing siRNA. (a) After 24 h Real-Time PCR was performed using primers designed on MagT1 
sequence. (b) Western blot was performed on cell extracts of LoVo-R 24, 48 and 72 h after transfection with 
siRNA against MagT1. Actin was used as a control of loading. Full-length blots and quantification are presented 
in Supplementary Figure S6B. (c) LoVo-R were counted every 24 h. Data are expressed as total cell number and 
refer to three separate experiments in triplicate ± standard deviation.
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Transmission Electron Microscopy (TEM). The semi-confluent cells were fixed overnight at 4 °C in a 
solution containing 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4), immobilized on a Nunc Sylgard 
coated Petri dish (ThermoFisher Scientific), rinsed twice in the same buffer for 20 min and processed for TEM. 
After post-fixation with 1% osmium tetroxide at 0 °C for 30 min, the 2D-monolayer cultures in situ on Petri 
were washed in distilled water, stained with 2% aqueous uranyl acetate, dehydrated in graded ethanols at 4 °C 
and embedded in Epon-Araldite resin. Ultra-thin sections cut by a Leica Supernova ultramicrotome (Reichert 
Ultracut E and UC7; Leica Microsystems) were stained with lead citrate and observed under a Zeiss EM10 elec-
tron microscope.
Real-Time PCR. Total RNA was extracted by the PureLink RNA Mini kit (Ambion). Single-stranded cDNA 
was synthesized using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and Real-time 
PCR was performed using TaqMan Gene Expression Assays (Life Technologies): Hs00918928_g1 (TRPM7) and 
MagT1 (Hs00997540_m1). The housekeeping gene GAPDH (Hs99999905_m1) was used as an internal reference 
gene. Relative changes in gene expression (defined as FC) were analyzed by the 2−ΔΔCt method32. Experiments 
were performed twice in triplicate.
Western Blot Analysis. Cells were lysed in 50 mM TrisHCl pH 8.0 containing 150 mM NaCl, 1 mM EDTA, 
1% NP-40. Cell extracts (100 μ g/lane) were resolved by 8 or 10% SDS-PAGE, transferred to nitrocellulose sheets at 
100 mA for 16 h, and probed with anti-TRPM7 (Bethyl), anti-MagT1 (ProteinTech), anti-PgP (ThermoScientific), 
and anti-actin (Sigma Aldrich) antibodies. Secondary antibodies were labelled with horseradish peroxidase (GE 
Healthcare). The SuperSignal chemiluminescence kit (Pierce) was used to detect immunoreactive proteins. All 
the results were reproduced at least three times and a representative Western blot is shown. Densitometric anal-
ysis was performed by the ImageJ software and ratio between the protein of interest and actin was calculated on 
three separate experiments (see Supplementary).
Statistical Analysis. Statistical significance was determined using Student’s t test and set as following: 
*P < 0.05, **P < 0.01, ***P < 0.001.
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